Wenjun Pi, Liang Cao, Qingli Wang, V.Wee Yong, Leiluo Yang, Mengzhou Xue
Neuroinflammation is a convergent feature of neurodegenerative diseases, hemorrhagic and ischemic stroke, and spinal cord injury. Central to this process is the Toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) signaling axis, which senses damage-associated molecular patterns to initiate innate immune responses. While the canonical inflammatory role of TLR4 is well-defined, recent evidence identifies it as a critical regulator of non-canonical cell death-including pyroptosis and necroptosis-and a requisite priming signal for NLRP3 inflammasome activation. This review examines the expanding complexity of TLR4/MyD88 signaling, moving beyond local central nervous system (CNS) activation to its regulation via the microbiota-gut-brain axis, metabolic endotoxemia, and epigenetic modifications such as miRNA and lncRNA networks. We synthesize these molecular insights within the context of specific pathologies, particularly Alzheimer’s disease, Parkinson’s disease, and traumatic CNS injury. Finally, we evaluate the translational potential of targeting this axis, highlighting the shift from broad-spectrum anti-inflammatories to precision strategies involving nanodelivery systems and immunometabolic modulation.